Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed, Inc. (Symbol: INSM) is a global biopharmaceutical company headquartered in Bridgewater, NJ, with a mission to transform the lives of patients with serious and rare diseases. The company is committed to developing and bringing to market therapies that significantly improve patient lives, focusing on the entire patient journey from diagnosis and treatment to daily living.
Insmed's flagship product, ARIKAYCE (amikacin liposome inhalation suspension), is approved in the US for treating Mycobacterium Avium Complex (MAC) lung disease in adult patients who have limited or no alternative treatment options. ARIKAYCE, utilizing Insmed's proprietary PULMOVANCE® liposomal technology, delivers amikacin directly to the lungs, reducing systemic exposure and associated toxicities. It is administered using the Lamira® Nebulizer System developed by PARI Pharma GmbH, known for its efficiency and portability.
The company’s clinical pipeline includes multiple promising candidates. Notable among them is Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1). It is being developed for treating non-cystic fibrosis bronchiectasis and other neutrophil-mediated diseases. Another significant pipeline product is TPIP (Treprostinil Palmitil Inhalation Powder), an inhaled formulation being evaluated for pulmonary arterial hypertension and other serious pulmonary disorders.
Insmed has demonstrated robust financial performance, with significant revenue growth driven by ARIKAYCE. The company continues to invest heavily in research and development, with plans to expand its product portfolio and market reach globally.
Insmed's strategic partnerships and collaborations play a crucial role in advancing its mission. These include collaborations with PARI Pharma for the Lamira® Nebulizer System and AstraZeneca AB for utilizing their expertise in respiratory diseases.
Recent updates include positive financial results for the third quarter of 2023, robust revenue growth from ARIKAYCE, and significant progress in clinical trials. Noteworthy are the topline results from the Phase 3 ASPEN study for Brensocatib, indicating its potential as a first-in-class treatment. Insmed plans to file a New Drug Application (NDA) with the FDA for Brensocatib by late 2024, aiming for a potential launch in 2025.
The company is also advancing its early-stage research engine, exploring innovative technologies such as artificial intelligence-driven protein engineering and gene therapy, positioning itself at the forefront of biopharmaceutical innovation.
Insmed Incorporated announced the granting of inducement awards to 10 new employees as part of their recruitment strategy. Each employee received options to purchase a total of 74,410 shares of common stock at an exercise price of $23.71, aligning with the market closing price on February 1, 2022. The options have a 10-year term with a four-year vesting schedule. Insmed focuses on transforming lives through treatments for serious and rare diseases, and it is advancing a pipeline targeting unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) will announce its fourth quarter and full year 2021 financial results on February 17, 2022. Management will also provide a business and pipeline update during a conference call from 8:00 to 9:30 a.m. ET. Interested parties can join by calling specified numbers or via webcast on the company's website. A replay of the call will be available for a month. Insmed's mission is to improve lives with therapies for serious diseases, and it has a robust pipeline addressing unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:45 p.m. ET. The event will be available via live webcast on the company's website, with an archived version accessible for 30 days post-event. Insmed is focused on transforming the lives of patients with serious and rare diseases, notably with its first commercial product targeting a chronic lung disease and an expanding pipeline for unmet needs.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to six new employees, totaling 43,610 stock options exercisable at $26.69 per share. These options come with a ten-year term and a four-year vesting schedule, with 25% vesting after one year and the remainder vesting semi-annually thereafter. This move, compliant with NASDAQ Listing Rule 5635(c)(4), aims to attract talent into the company. Insmed focuses on treating serious and rare diseases, with an approved therapy for a chronic lung disease and a pipeline of investigational therapies.
Insmed has announced the grant of inducement awards to 15 new employees, approved by its Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 52,180 shares at an exercise price of $31.05, the closing price as of November 1, 2021. The options have a ten-year term and will vest over four years, with the first 25% vesting after one year, followed by 12.5% every six months. Insmed aims to improve the lives of patients with serious and rare diseases and continues expanding its pipeline of therapies.
Insmed Incorporated (Nasdaq: INSM) announced its participation in three upcoming virtual investor conferences aimed at discussing the company's developments in biopharmaceuticals. On November 9, 2021, at 10:30 a.m. ET, Insmed will join the Credit Suisse 30th Annual Virtual Healthcare Conference. This will be followed by the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 8:40 a.m. ET, and the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 8:00 a.m. ET. All events will be webcast live and archived for 30 days.
Insmed Incorporated (Nasdaq: INSM) reported Q3 2021 revenue of $46.8 million, up from $43.6 million in Q3 2020. The company experienced a GAAP net loss of $112.7 million or $0.96 per share, widening from a loss of $63.7 million or $0.63 per share year-over-year. Key developments include strong initial uptake of ARIKAYCE in Japan and ongoing clinical trials for brensocatib and TPIP. Insmed ended the quarter with $846.6 million in cash and cash equivalents, positioning it well for future investments and growth.
Insmed Incorporated (Nasdaq:INSM) will release its third quarter 2021 financial results on October 28, 2021. A conference call will follow at 8:30 a.m. ET to discuss the results and offer a business update. Participants can join via phone or through a live webcast on the company's website. Insmed focuses on rare and serious diseases, with its first product being a therapy approved in multiple regions, including the US, Europe, and Japan. The company is also developing investigational therapies in high-need areas.
Insmed announced on October 5, 2021, that it has granted inducement awards to 11 new employees. These awards consist of options to purchase a total of 67,760 shares of common stock at an exercise price of $27.38, the closing price on the grant date. The options feature a ten-year term with a four-year vesting schedule, where 25% vests after the first year and 12.5% every six months thereafter, contingent on continued employment. This initiative is aligned with NASDAQ Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
What is Insmed's primary mission?
What is ARIKAYCE?
What are Brensocatib and TPIP?
Where is Insmed headquartered?
What are Insmed's recent financial highlights?
What are the strategic partnerships of Insmed?
What are the latest developments in Insmed's clinical trials?
What is Insmed's approach to early-stage research?
What is the Lamira® Nebulizer System?
When does Insmed plan to file an NDA for Brensocatib?
